Origenis presents preclinical data for ORI-15412, a novel, fully brain penetrant CDK9 inhibitor at the AACR in Chicago

Origenis presents preclinical data for ORI-15412, a novel, fully brain penetrant CDK9 inhibitor at the AACR in Chicago. Two posters are available for download as pdf:

Mastering metastases by novel selective CDK9 inhibitor ORI-15412

The novel selective CDK9 Inhibitor ORI-15412 reduces PD-L1 expression and drives the efficacy in combination therapies for melanoma and triple-negative breast cancer

ORI-15412 represents the first clinics-ready product that has emerged from Origenis CDKspot technology platform, that yields highly specific first-in-class and best-in-class CDK inhibitors for Oncology and Neurology applications.